APA
Nelson D. R., Cooper J. N., Lalezari J. P., Lawitz E., Pockros P. J., Gitlin N., Freilich B. F., Younes Z. H., Harlan W., Ghalib R., Oguchi G., Thuluvath P. J., Ortiz-Lasanta G., Rabinovitz M., Bernstein D., Bennett M., Hawkins T., Ravendhran N., Sheikh A. M., Varunok P., Kowdley K. V., Hennicken D., McPhee F., Rana K. & Hughes E. A. (20150601). All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. : Hepatology (Baltimore, Md.).
Chicago
Nelson David R, Cooper James N, Lalezari Jacob P, Lawitz Eric, Pockros Paul J, Gitlin Norman, Freilich Bradley F, Younes Ziad H, Harlan William, Ghalib Reem, Oguchi Godson, Thuluvath Paul J, Ortiz-Lasanta Grisell, Rabinovitz Mordechai, Bernstein David, Bennett Michael, Hawkins Trevor, Ravendhran Natarajan, Sheikh Aasim M, Varunok Peter, Kowdley Kris V, Hennicken Delphine, McPhee Fiona, Rana Khurram and Hughes Eric A. 20150601. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. : Hepatology (Baltimore, Md.).
Harvard
Nelson D. R., Cooper J. N., Lalezari J. P., Lawitz E., Pockros P. J., Gitlin N., Freilich B. F., Younes Z. H., Harlan W., Ghalib R., Oguchi G., Thuluvath P. J., Ortiz-Lasanta G., Rabinovitz M., Bernstein D., Bennett M., Hawkins T., Ravendhran N., Sheikh A. M., Varunok P., Kowdley K. V., Hennicken D., McPhee F., Rana K. and Hughes E. A. (20150601). All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. : Hepatology (Baltimore, Md.).
MLA
Nelson David R, Cooper James N, Lalezari Jacob P, Lawitz Eric, Pockros Paul J, Gitlin Norman, Freilich Bradley F, Younes Ziad H, Harlan William, Ghalib Reem, Oguchi Godson, Thuluvath Paul J, Ortiz-Lasanta Grisell, Rabinovitz Mordechai, Bernstein David, Bennett Michael, Hawkins Trevor, Ravendhran Natarajan, Sheikh Aasim M, Varunok Peter, Kowdley Kris V, Hennicken Delphine, McPhee Fiona, Rana Khurram and Hughes Eric A. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. : Hepatology (Baltimore, Md.). 20150601.